- Mothe, Beatriz;
- Llano, Anuska;
- Ibarrondo, Javier;
- Daniels, Marcus;
- Miranda, Cristina;
- Zamarreño, Jennifer;
- Bach, Vanessa;
- Zuniga, Rosario;
- Pérez-Álvarez, Susana;
- Berger, Christoph T;
- Puertas, Maria C;
- Martinez-Picado, Javier;
- Rolland, Morgane;
- Farfan, Marilu;
- Szinger, James J;
- Hildebrand, William H;
- Yang, Otto O;
- Sanchez-Merino, Victor;
- Brumme, Chanson J;
- Brumme, Zabrina L;
- Heckerman, David;
- Allen, Todd M;
- Mullins, James I;
- Gómez, Guadalupe;
- Goulder, Philip J;
- Walker, Bruce D;
- Gatell, Jose M;
- Clotet, Bonaventura;
- Korber, Bette T;
- Sanchez, Jorge;
- Brander, Christian
Abstract Background The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. Methods Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. Results For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. Conclusions The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections.